Abiraterone was associated with a low response rate among patients with recurrent epithelial ovarian cancer (EOC), but 1 patient with androgen receptor (AR)-positive low grade serous EOC achieved sustained clinical benefit, according to a study presented at the 2016 European Society for Medical Oncology (ESMO) 2016 Congress1
The androgen receptor is frequently expressed in EOC; researchers evaluated the clinical activity of abiraterone, an androgen synthesis inhibitor widely used in prostate cancer, among patients with EOC.
For the multicenter, open-label, phase 2 CORAL study (Cancer of the Ovary Abiraterone trial; EudraCT Number: 2013-000293-29), researchers enrolled 42 patients with EOC who had disease progression within 12 months of last systemic therapy and no prior treatment with hormonal anti-cancer agents. Of those, 83% had high grade serous EOC, 47% had received 3 or more prior lines of therapy, and 69% were AR-positive.
The overall response rate was 2% with abiraterone and prednisone daily. The 1 patient who achieved a response had AR-positive low grade serous EOC and the response lasted 47 weeks.
The clinical benefit rate, which included overall responses and stable disease, was 26% at 12 weeks and 28% among AR-positive patients.
Of those, 14% had disease control for 6 months or longer and 1 patient continues to receive abiraterone.
Further investigation is warranted to assess the activity of abiraterone among patients with low grade serous EOC.
- Banerjee S, Kilburn L, Bowen R, et al. Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052). Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.